GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:019873814 | Prostate | Tumor | cell-cell signaling by wnt | 131/3246 | 446/18723 | 1.61e-10 | 9.69e-09 | 131 |
GO:200123619 | Prostate | Tumor | regulation of extrinsic apoptotic signaling pathway | 59/3246 | 151/18723 | 1.86e-10 | 1.09e-08 | 59 |
GO:000704415 | Prostate | Tumor | cell-substrate junction assembly | 43/3246 | 95/18723 | 2.33e-10 | 1.34e-08 | 43 |
GO:005122218 | Prostate | Tumor | positive regulation of protein transport | 97/3246 | 303/18723 | 2.67e-10 | 1.48e-08 | 97 |
GO:003596719 | Prostate | Tumor | cellular response to topologically incorrect protein | 49/3246 | 116/18723 | 2.68e-10 | 1.48e-08 | 49 |
GO:190165418 | Prostate | Tumor | response to ketone | 70/3246 | 194/18723 | 2.69e-10 | 1.48e-08 | 70 |
GO:005149517 | Prostate | Tumor | positive regulation of cytoskeleton organization | 78/3246 | 226/18723 | 3.05e-10 | 1.65e-08 | 78 |
GO:007097216 | Prostate | Tumor | protein localization to endoplasmic reticulum | 36/3246 | 74/18723 | 5.66e-10 | 2.95e-08 | 36 |
GO:004440919 | Prostate | Tumor | entry into host | 58/3246 | 151/18723 | 5.78e-10 | 2.99e-08 | 58 |
GO:001604916 | Prostate | Tumor | cell growth | 137/3246 | 482/18723 | 7.01e-10 | 3.51e-08 | 137 |
GO:200123517 | Prostate | Tumor | positive regulation of apoptotic signaling pathway | 51/3246 | 126/18723 | 7.27e-10 | 3.59e-08 | 51 |
GO:003459919 | Prostate | Tumor | cellular response to oxidative stress | 92/3246 | 288/18723 | 8.68e-10 | 4.22e-08 | 92 |
GO:000072315 | Prostate | Tumor | telomere maintenance | 52/3246 | 131/18723 | 1.13e-09 | 5.43e-08 | 52 |
GO:003158916 | Prostate | Tumor | cell-substrate adhesion | 109/3246 | 363/18723 | 1.41e-09 | 6.71e-08 | 109 |
GO:000164915 | Prostate | Tumor | osteoblast differentiation | 77/3246 | 229/18723 | 1.55e-09 | 7.26e-08 | 77 |
GO:190018014 | Prostate | Tumor | regulation of protein localization to nucleus | 53/3246 | 136/18723 | 1.72e-09 | 7.91e-08 | 53 |
GO:005110119 | Prostate | Tumor | regulation of DNA binding | 48/3246 | 118/18723 | 1.87e-09 | 8.43e-08 | 48 |
GO:003220414 | Prostate | Tumor | regulation of telomere maintenance | 37/3246 | 80/18723 | 1.97e-09 | 8.81e-08 | 37 |
GO:004671819 | Prostate | Tumor | viral entry into host cell | 55/3246 | 144/18723 | 2.03e-09 | 8.89e-08 | 55 |
GO:190018214 | Prostate | Tumor | positive regulation of protein localization to nucleus | 39/3246 | 87/18723 | 2.24e-09 | 9.59e-08 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RP1 | SNV | Missense_Mutation | novel | c.81G>C | p.Leu27Phe | p.L27F | P56715 | protein_coding | tolerated(0.65) | benign(0.007) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
RP1 | SNV | Missense_Mutation | rs747714373 | c.2978C>G | p.Ser993Cys | p.S993C | P56715 | protein_coding | deleterious(0.02) | possibly_damaging(0.781) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RP1 | SNV | Missense_Mutation | | c.4362C>A | p.Ser1454Arg | p.S1454R | P56715 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
RP1 | SNV | Missense_Mutation | novel | c.1138N>T | p.Pro380Ser | p.P380S | | protein_coding | deleterious(0.04) | probably_damaging(0.923) | TCGA-A2-A3XV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RP1 | SNV | Missense_Mutation | novel | c.983N>G | p.Lys328Arg | p.K328R | | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A7-A4SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RP1 | SNV | Missense_Mutation | | c.2516N>C | p.Gln839Pro | p.Q839P | P56715 | protein_coding | deleterious(0.03) | possibly_damaging(0.641) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RP1 | SNV | Missense_Mutation | novel | c.4466C>T | p.Ala1489Val | p.A1489V | P56715 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
RP1 | SNV | Missense_Mutation | | c.2675N>T | p.Ala892Val | p.A892V | P56715 | protein_coding | tolerated(0.14) | benign(0.039) | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
RP1 | SNV | Missense_Mutation | | c.1895N>T | p.Ser632Leu | p.S632L | P56715 | protein_coding | tolerated(0.2) | benign(0.042) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RP1 | SNV | Missense_Mutation | | c.4027N>A | p.Asp1343Asn | p.D1343N | P56715 | protein_coding | tolerated(0.07) | benign(0) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |